Progenika Inc

Progenika Inc.

PROGENIKA, Inc. was launched in Boston, MA in 2007, as a spin-off company of Progenika Biopharma S.A..

The company will validate, analyze and commercialize PROGENIKA DNA microarrays in USA under FDA and CLIA lab regulations. A strong sales, marketing and business development force will be established and consolidate links with US pharmaceutical, biotechnological and Health Care insurance companies, as well as with US clinical laboratories, physicians and patient associations.

Proteomika, S.L.

Proteomika is a biotechnology company owned by Progenika Group which specializes in diagnostic tests for complex diseases. We are committed to patients and all our efforts are focused on the development of tools to diagnose and treat these diseases. Proteomika’s mission is to provide the medical community improved tools for non-invasive diagnosis, as well as for monitoring and predicting patient response to therapy, in order to personalize the treatment regime.

Abyntek Biopharma S.L.

Abyntek Biopharma S.L. is a privately owned biotechnology company that centers its activity in developing, producing and commercializing antigens and antibodies.

A strong investment in R&D constitutes one of the fundamental values on which the business strategy of Abyntek is based. The R&D activities of Abyntek focus on two main areas:

• The development of new technologies to produce monoclonal antibodies.
• The development of diagnostic and prognostic products, as well as products to predict the response to treatment and for the treatment of lung diseases.

Brainco

BRAINco offers a personal medicine approach to the psychiatric, neurologic and degenerative diseases, including diagnosis and treatment of these disorders.

Based on this know-how, BRAINco is developing diagnostics tools and compound treatments for Nervous System diseases, including psychiatric and some neurological disorders. BRAINco has identified new therapeutic targets and its developing treatments for Schizophrenia, Bipolar Disorder, Major Depression, Multiple Sclerosis, etc.

In the last two years, a number of significant altered proteins in postmortem human brain, have been identified in the patients’ brains. These proteins have been validated and BRAINco is now developing a complete panel of assays to develop compounds against this targets.

Transgenic mice have been created overexpressing the target proteins. BRAINco is characterizing these mice at cellular, biochemical and behavioral levels.